Argenica Phase 2 Trial Confirms Safety of ARG-007 and Identifies At-Risk Patient Group Benefit

Argenica Therapeutics Limited (ASX: AGN) announced top-line results from its Phase 2 SEANCON trial of ARG-007 in acute ischaemic stroke (AIS) patients. The achievement of the primary endpoint demonstrated that ARG-007 is safe, well-tolerated, and does not significantly differ in adverse events when compared to a placebo. Importantly, no drug-to-drug interactions were observed with standard thrombolytic therapies, allowing ARG-007 to be administered regardless of clot-dissolving treatment.

While the secondary endpoint did not show an overall treatment effect across all patients, a predefined subgroup of high-risk “rapid progressors” with slow collateral blood flow demonstrated a 15% reduction in infarct volume at Day 3, supporting Argenica’s hypothesis that these patients are most likely to benefit. The company will now refine future trial designs to focus on this subgroup, with current funding of AU$7 million and an expected R&D rebate of AU$3.5–4 million backing further development.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com